PF-07104091 as a Single Agent and in Combination Therapy (NCT04553133)

🧪 Interventions in This Study

• PF-07104091 monotherapy dose escalation (DRUG)
• PF-07104091 + palbociclib + fulvestrant (DRUG)
• PF-07104091 + palbociclib + letrozole (DRUG)
• PF-07104091 monotherapy dose expansion (ovarian) (DRUG)
• PF-07104091 monotherapy dose expansion (SCLC) (DRUG)
• PF-07104091 + Fulvestrant (post CDK4/6) (DRUG)
• PF-0704091 + Fulvestrant (post CDK4/6) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• Medical Oncology & Hematology Associates DBA Mission Cancer and Blood — Clive, Iowa
• Des Moines Oncology Research Association — Des Moines, Iowa
• Medical Oncology & Hematology Associates DBA Mission Cancer and Blood — Des Moines, Iowa
• Medical Oncology & Hematology Associates DBA Mission Cancer and Blood — Des Moines, Iowa
• Norton Hospital — Louisville, Kentucky
• Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
• Norton Cancer Institute, Audubon — Louisville, Kentucky
• Norton Brownsboro Hospital — Louisville, Kentucky
• Norton Cancer Institute, Brownsboro Campus — Louisville, Kentucky
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute - Chestnut Hill — Newton, Massachusetts
• Memorial Sloan Kettering Monmouth — Middletown, New Jersey
• Memorial Sloan Kettering Cancer Center (IDS Pharmacy) — Long Island City, New York
• Laura & Isaac Perlmutter Cancer Center - NYU ACC — New York, New York
• NYU Langone Medical Center (Tisch Hospital) — New York, New York
• White Plains Hospital — White Plains, New York
• UVA Breast Care Center — Charlottesville, Virginia
• Centro de Investigaciones Medicas y Desarrollo LC — Buenos Aires, Buenos Aires F.D.
• Complex Oncology Center - Plovdiv EOOD — Plovdiv,
• Complex Oncology Center - Shumen — Shumen,
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Small Cell Lung Cancer

• Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) — Chandler, Arizona
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Irvine, California
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Tucson, Arizona
• Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms — Rockville, Maryland

Explore by condition: All Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.